# EDGAR Filing Document

**Accession Number:** 0001129928
**File Stem:** 0001104659-26-040984
**Filing Date:** 2026-4
**Character Count:** 3332
**Document Hash:** 41296638ccffd9f031a29c85013850c1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-040984.hdr.sgml**: 20260408

**ACCESSION NUMBER**: 0001104659-26-040984

**CONFORMED SUBMISSION TYPE**: AW

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260408

**DATE AS OF CHANGE**: 20260408

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOLYTICS BIOTECH INC
- **CENTRAL INDEX KEY:** 0001129928
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980541667
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** AW

**SEC ACT:**
- **SEC FILE NUMBER:** 333-182260
- **FILM NUMBER:** 26848842

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 325, 4350 EXECUTIVE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 4036707377

**MAIL ADDRESS:**
- **STREET 1:** SUITE 325, 4350 EXECUTIVE DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**Oncolytics Biotech Inc.**

**4350 Executive Drive, Suite 325**

**San Diego, California 92121**

April 8, 2026

***Via EDGAR***

Office of International Corporate Finance

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Oncolytics Biotech Inc.** |

---

**Withdrawal of Post-Effective Amendments to Registration Statements on Form F-10**

To Whom It May Concern:

Pursuant to Rule 477(a) of the U.S. Securities Act of 1933, as amended, Oncolytics Biotech Inc. (the "***Company***") hereby requests the withdrawal of (i) Post-Effective Amendment No. 1 to each of the Company's registration statements on Form F-10 (File Nos. 333-140460, 333-140529, 333-151513, 333-167250, 333-182260, 333-197633, 333-224432, 333-239025, 333-265510, and 333-281009) (collectively, the "***Registration Statements***"), filed by the Company with the U.S. Securities and Exchange Commission (the "***Commission***") on April 1, 2026 (Accession Nos. 0001104659-26-038088, 0001104659-26-038089, 0001104659-26-038090, 0001104659-26-038091, 0001104659-26-038093, 0001104659-26-038094, 0001104659-26-038095, 0001104659-26-038097, 0001104659-26-038098, and 0001104659-26-038099) and (ii) Post-Effective Amendment No. 2 to each of the Registration Statements, filed by the Company with the Commission on April 6, 2026 (Accession Nos. 0001104659-26-040020, 0001104659-26-040021, 0001104659-26-040022, 0001104659-26-040023, 0001104659-26-040024, 0001104659-26-040025, 0001104659-26-040026, 0001104659-26-040027, 0001104659-26-040028, and 0001104659-26-040029) (together, the "***Post-Effective Amendments***").

The Company is requesting withdrawal of the Post-Effective Amendments in order to file a replacement post-effective amendment reflecting a revised proposed effective time and date pursuant to Rule 467(b). No securities were sold pursuant to the Post-Effective Amendments.

Please direct any questions or comments concerning this request to the Company's counsel, Latham & Watkins LLP, by calling Christopher J. Clark at (202) 637-2374.

---

| |
|:---|
| Sincerely, |
| **ONCOLYTICS BIOTECH INC.** |
| /s/ Kirk Look |
| Kirk Look |
| Chief Financial Officer |

---

cc: Jared Kelly, Chief Executive Officer, Oncolytics Biotech Inc.

Christopher J. Clark, Latham & Watkins LLP